Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02907918 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
A Phase 2 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02907918 is a Phase 2 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 26 participants.
The verdict
NCT02907918, a Phase 2 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.
Interventions
- DRUG Letrozole
- DRUG Palbociclib
- DRUG Goserelin
- BIOLOGICAL Trastuzumab
- PROCEDURE Breast surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-06-30 |
| Est. Completion | 2020-09-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02907918
The ClinicalTrials.gov registry entry for NCT02907918 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Letrozole is the first listed.
NCT02907918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02907918 about?
NCT02907918 is a clinical study titled "Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer". The investigators propose to influence estrogen receptor (ER) signaling by combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer.
What is the current status of trial NCT02907918?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2017-06-30. Estimated completion is 2020-09-23.
What interventions are being tested in trial NCT02907918?
The interventions under investigation include: Letrozole (DRUG), Palbociclib (DRUG), Goserelin (DRUG), Trastuzumab (BIOLOGICAL), Breast surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02907918?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.